KR20140077169A - 호흡기 세포 융합 바이러스에 대한 재조합 나노입자 ｒｓｖ ｆ 백신 - Google Patents

호흡기 세포 융합 바이러스에 대한 재조합 나노입자 ｒｓｖ ｆ 백신 Download PDF

Info

Publication number
KR20140077169A
KR20140077169A KR1020147009538A KR20147009538A KR20140077169A KR 20140077169 A KR20140077169 A KR 20140077169A KR 1020147009538 A KR1020147009538 A KR 1020147009538A KR 20147009538 A KR20147009538 A KR 20147009538A KR 20140077169 A KR20140077169 A KR 20140077169A
Authority
KR
South Korea
Prior art keywords
rsv
protein
seq
modified
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147009538A
Other languages
English (en)
Korean (ko)
Inventor
게일 스미스
잉윈 우
마이클 마서리
예 류
Original Assignee
노바백스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바백스, 인코포레이티드 filed Critical 노바백스, 인코포레이티드
Publication of KR20140077169A publication Critical patent/KR20140077169A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147009538A 2011-09-30 2012-09-27 호흡기 세포 융합 바이러스에 대한 재조합 나노입자 ｒｓｖ ｆ 백신 Withdrawn KR20140077169A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161542040P 2011-09-30 2011-09-30
US61/542,040 2011-09-30
US201161542721P 2011-10-03 2011-10-03
US61/542,721 2011-10-03
US201261611834P 2012-03-16 2012-03-16
US61/611,834 2012-03-16
US201261614286P 2012-03-22 2012-03-22
US61/614,286 2012-03-22
PCT/US2012/057546 WO2013049342A1 (en) 2011-09-30 2012-09-27 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus

Publications (1)

Publication Number Publication Date
KR20140077169A true KR20140077169A (ko) 2014-06-23

Family

ID=47996397

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147009538A Withdrawn KR20140077169A (ko) 2011-09-30 2012-09-27 호흡기 세포 융합 바이러스에 대한 재조합 나노입자 ｒｓｖ ｆ 백신

Country Status (14)

Country Link
US (4) US20130122032A1 (https=)
EP (1) EP2760469A4 (https=)
JP (1) JP2014530010A (https=)
KR (1) KR20140077169A (https=)
CN (2) CN105381457A (https=)
AU (1) AU2013201495B2 (https=)
BR (1) BR112014007616A2 (https=)
CA (1) CA2849471A1 (https=)
HK (1) HK1222125A1 (https=)
IL (1) IL231637A0 (https=)
MX (1) MX2014003777A (https=)
RU (1) RU2014117068A (https=)
SG (2) SG10201602434UA (https=)
WO (1) WO2013049342A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020076141A1 (ko) * 2018-10-12 2020-04-16 에스케이바이오사이언스 주식회사 재조합 rsv 생백신주 및 이의 제조 방법
KR20230089648A (ko) * 2021-12-14 2023-06-21 경희대학교 산학협력단 Rsv 항원 단백질을 포함하는 바이러스 유사입자 및 이를 이용한 백신

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
HK1214138A1 (zh) * 2013-04-08 2016-07-22 米迪缪尼有限公司 疫苗组合物及使用方法
JP2016533332A (ja) * 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
CN105087643A (zh) * 2014-04-16 2015-11-25 中国科学院上海巴斯德研究所 重组表达人呼吸道合胞病毒f1蛋白胞外区的方法及表达系统
WO2015195961A1 (en) * 2014-06-18 2015-12-23 Georgia State University And Research Foundation, Inc. Recombinant rsv reporter virus
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CA2996762A1 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
US10538557B2 (en) * 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
CA2996007A1 (en) * 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
CN106547635B (zh) 2015-09-18 2020-10-09 阿里巴巴集团控股有限公司 一种作业的操作重试方法和装置
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
IL262108B2 (en) * 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
CN106124767A (zh) * 2016-05-12 2016-11-16 广州瑞辉生物科技股份有限公司 呼吸道合胞病毒IgA抗体检测试纸条及其检测方法
EP3518967A4 (en) 2016-10-03 2020-04-29 University of Massachusetts Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv)
MX2019010948A (es) * 2017-03-15 2020-01-09 Novavax Inc Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile.
HUE073526T2 (hu) 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
CN107050446B (zh) * 2017-04-19 2020-08-11 武汉博沃生物科技有限公司 经修饰的季节流感-rsv联合疫苗及其制备方法
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
WO2019063844A1 (en) * 2017-09-29 2019-04-04 Universiteit Antwerpen VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS
WO2019169120A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN120227451A (zh) 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
EP3873517A4 (en) 2018-10-29 2022-09-28 Emory University RSV VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF
KR102725189B1 (ko) * 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
EP3932424A4 (en) * 2019-02-28 2022-10-12 KM Biologics Co., Ltd. Rsv f/g chimeric vaccine
CN110229219B (zh) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20230070886A1 (en) * 2020-01-27 2023-03-09 Novavax, Inc. Coronavirus vaccine formulations
AU2021250630A1 (en) * 2020-04-02 2022-10-20 Janssen Vaccines & Prevention B.V. Stabilized vaccine compositions
KR102721070B1 (ko) * 2020-11-27 2024-10-24 한국과학기술연구원 Rsvf를 발현하는 엑소좀 및 이의 용도
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
WO2023091766A2 (en) * 2021-11-19 2023-05-25 RNAimmune, Inc. Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
WO2024050015A1 (en) * 2022-09-01 2024-03-07 Novavax, Inc. Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions
WO2024093554A1 (zh) * 2022-11-04 2024-05-10 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
EP4736871A1 (en) * 2023-06-21 2026-05-06 Shenzhen Shenxin Biotechnology Co., Ltd. Respiratory syncytial virus (rsv) vaccine
WO2024259624A1 (en) * 2023-06-21 2024-12-26 Shenzhen Genius Biotech Service Co. Ltd A modified rsv f protein, a nanoparticle, a composition and a vaccine against respiratory syncytial virus infection
WO2025026448A1 (zh) * 2023-08-03 2025-02-06 广州穗和生物技术有限公司 修饰的呼吸道合胞病毒f蛋白及其用途
CN119569835A (zh) * 2023-09-07 2025-03-07 北京科兴中维生物技术有限公司 呼吸道合胞病毒f蛋白及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622574A4 (en) * 2003-04-25 2006-10-18 Medimmune Vaccines Inc EXPRESSION SYSTEMS OF RECOMBINANT PARAINFLUENZA VIRUSES AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS
WO2008114149A2 (en) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
US20110008838A1 (en) * 2007-07-19 2011-01-13 Gale Smith Chimeric varicella zoster virus virus-like particles
JP5711972B2 (ja) * 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
WO2009108689A1 (en) * 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
KR101027159B1 (ko) * 2008-07-28 2011-04-05 뮤추얼아이피서비스(주) 타겟 영상 검출 장치 및 그 방법
WO2010077712A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
PL2370099T3 (pl) * 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020076141A1 (ko) * 2018-10-12 2020-04-16 에스케이바이오사이언스 주식회사 재조합 rsv 생백신주 및 이의 제조 방법
KR20230089648A (ko) * 2021-12-14 2023-06-21 경희대학교 산학협력단 Rsv 항원 단백질을 포함하는 바이러스 유사입자 및 이를 이용한 백신

Also Published As

Publication number Publication date
WO2013049342A1 (en) 2013-04-04
RU2014117068A (ru) 2015-11-10
EP2760469A4 (en) 2015-03-18
US20170319682A1 (en) 2017-11-09
US20130122032A1 (en) 2013-05-16
BR112014007616A2 (pt) 2017-04-04
CN104080476A (zh) 2014-10-01
AU2013201495A1 (en) 2013-04-18
HK1222125A1 (zh) 2017-06-23
AU2013201495B2 (en) 2015-12-03
IL231637A0 (en) 2014-05-28
EP2760469A1 (en) 2014-08-06
US20150335730A1 (en) 2015-11-26
SG11201400999VA (en) 2014-07-30
MX2014003777A (es) 2015-05-15
SG10201602434UA (en) 2016-05-30
CN105381457A (zh) 2016-03-09
CA2849471A1 (en) 2013-04-04
JP2014530010A (ja) 2014-11-17
US20150306207A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
US12357684B2 (en) Modified RSV F proteins and methods of their use
KR20140077169A (ko) 호흡기 세포 융합 바이러스에 대한 재조합 나노입자 ｒｓｖ ｆ 백신
KR20150138184A (ko) 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
US11446374B2 (en) Modified RSV F proteins and methods of their use
HK1161690B (en) Modified rsv f proteins and methods of their use
HK1228754A1 (en) Modified rsv f proteins and methods of their use
HK1228754B (en) Modified rsv f proteins and methods of their use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000